Study confirms GSK-Vir antibody drug reduces hospitalisation, death in Covid-19 patients

The drugmakers also said on Monday the US National Institutes of Health (NIH) has recommended sotrovimab to treat high-risk, non-hospitalized patients with mild-to-moderate Covid-19